DOCSLIB.ORG

Malignant Pleural Mesothelioma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Malignant Pleural Mesothelioma our Pleaseonline completesurvey at NCCN.org/patients/survey NCCN GUIDELINES FOR PATIENTS® Version 1.2016 Malignant Pleural Mesothelioma Presented with support from: Available online at NCCN.org/patients Ü Malignant Pleural Mesothelioma that you have cancer LEARNING can be overwhelming. The goal of this book is to help you get the best care. It explains which tests and treatments are recommended by experts for malignant pleural mesothelioma. The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 27 of the world’s leading cancer centers. Experts from NCCN have written treatment guidelines for doctors who treat mesothelioma. These treatment guidelines suggest what the best practice is for cancer care. The information in this patient book is based on the guidelines written for doctors. This book focuses on the treatment of mesothelioma. Key points of the book are summarized in the NCCN Quick Guide™ series Malignant Pleural Mesothelioma. NCCN also offers patient books on breast cancer, lung cancer, melanoma, and many other cancer types. Visit NCCN.org/patients for the full library of patient books as well as other patient and caregiver resources. NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 1 About These patient guides for cancer care are produced by the National Comprehensive Cancer Network® (NCCN®). The mission of NCCN is to improve cancer care so people can live better lives. At the core of NCCN are the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). NCCN Guidelines® contain information to help health care workers plan the best cancer care. They list options for cancer care that are most likely to have the best results. The NCCN Guidelines for Patients® present the information from the NCCN Guidelines in an easy-to-learn format. Panels of experts create the NCCN Guidelines. Most of the experts are from NCCN Member Institutions. Panelists may include surgeons, radiation oncologists, medical oncologists, and patient advocates. Recommendations in the NCCN Guidelines are based on clinical trials and the experience of the panelists. The NCCN Guidelines are updated at least once a year. When funded, the patient books are updated to reflect the most recent version of the NCCN Guidelines for doctors. For more information about the NCCN Guidelines, visit NCCN.org/clinical.asp. Dorothy A. Shead, MS Alycia Corrigan Susan Kidney Director, Patient and Medical Writer Graphic Design Clinical Information Specialist Operations Rachael Clarke Guidelines Data and Kimberly Williams Laura J. Hanisch, PsyD Layout Coordinator Graphic Design and Medical Writer/Patient Production Specialist Information Specialist NCCN Foundation was founded by NCCN to raise funds for patient education based on the NCCN Guidelines. NCCN Foundation offers guidance to people with cancer and their caregivers at every step of their cancer journey. This is done by sharing key information from the world’s leading cancer experts. This information can be found in a library of NCCN Guidelines for Patients® and other patient education resources. NCCN Foundation is also committed to advancing cancer treatment by funding the nation’s promising doctors at the center of cancer research, education, and progress of cancer therapies. For more information about NCCN Foundation, visit NCCNFoundation.org. © 2016 National Comprehensive Cancer Network, Inc. All rights reserved. NCCN Guidelines for Patients® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. National Comprehensive Cancer Network (NCCN) • 275 Commerce Drive, Suite 300 • Fort Washington, PA 19034 • 215.690.0300 NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 2 Supporters Endorsed and sponsored in part by Mesothelioma Applied® Research Foundation Pursuant to its mission to eradicate mesothelioma, the Mesothelioma Applied® Research Foundation supports all efforts to help patients find, understand, and undergo critical and life-saving treatments. We endorse this guide as a valuable and empowering resource for patients. curemeso.org NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 3 NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 4 Malignant Pleural Mesothelioma Contents 6 How to use this book 29 Part 5 Supportive care 7 Part 1 Presents the recommended treatments About mesothelioma for the physical and emotional challenges Explains malignant pleural mesothelioma of mesothelioma. and the risk factors for this cancer. 33 Part 6 12 Part 2 Making treatment decisions Testing for mesothelioma Offers information to help you and your Explains when you should be tested and doctors create a good treatment plan for the tests used. you. 17 Part 3 39 Glossary Treatment planning Dictionary Describes the tests used to plan Acronyms treatment based on how far the cancer has spread. 48 NCCN Panel Members 21 Part 4 49 NCCN Member Institutions Treatment guide Presents the recommended treatment 50 Index options for malignant pleural mesothelioma. NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 5 How to use this book Who should read this book? Help! What do the words mean? Mesothelioma is a rare cancer of the mesothelium— a layer of cells that makes fluid. Mesothelioma In this book, many medical words are included. can start in the lining of the abdomen (peritoneal These are words you will likely hear from your mesothelioma), heart (pericardial mesothelioma), treatment team. Most of these words may be new to testicles (testicular mesothelioma), or lungs (pleural you, and it may be a lot to learn. mesothelioma). It is a rare type of cancer. This book focuses on mesothelioma that starts in the lining of Don’t be discouraged as you read. Keep reading the lungs. Patients and those who support them may and review the information. Feel free to ask your find this book helpful. treatment team to explain a word or phrase that you do not understand. Words that you may not know are defined in the text Does the whole book apply or in the Dictionary. Acronyms are also defined when to me? first used and in the Glossary. Acronyms are short words formed from the first letters of several words. This book includes information for many situations. One example is CT for computed tomography. Your medical team can help. They can point out what parts of the book apply to you. They can also give you more information. As you read through this book, you may find it helpful to make a list of questions to ask your doctors. The recommendations in this book are based on science and the experience of NCCN experts. However, these recommendations may not be right for you. Your doctors may suggest other tests or treatments based on your health and other factors. If other suggestions are given, feel free to ask your treatment team questions. NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 6 1 About mesothelioma 8 What is a mesothelium? 8 How does mesothelioma start? 10 What are the risk factors? 11 Review NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, Version 1.2016 7 What is a mesothelium? About mesothelioma 1 How does mesothelioma start? In Part 1, you will learn about cancer How does mesothelioma start? cells and where mesothelioma grows in the body. Cancer is a disease of cells. Abnormal changes (mutations) in genes can turn normal cells into cancer cells. Genes are instructions in cells for making new cells and controlling how cells behave. Gene mutations cause cancer cells to act differently What is a mesothelium? than normal cells. The lungs are covered by a double layer of thin Normal cells grow and then divide to form new cells tissue called the pleura. The pleura protects and as the body needs them. When normal cells grow old cushions the lungs. It has an inner layer called the or get damaged, they die. Cancer cells don’t do this. visceral pleura. It is directly attached to the lungs and Cancer cells make new cells that aren’t needed and extends down into the spaces between the lobes don’t die quickly when old or damaged. Over time, of the lungs. The outer layer is calleed the parietal the cancer cells grow and divide enough to form a pleura. It lines the chest wall and has contact with mass called the primary tumor. If the primary tumor many body parts in the chest. See Figure 1. isn’t treated, it can grow and invade nearby tissues and organs, such as the lungs. The chest wall is the layer of muscle and bones under the skin in the chest area. The pleura is made Unlike normal cells, cancer cells can spread and of mesothelium and connective tissue. form tumors in other parts of the body. Cancer that has spread is called a metastasis. Cancer cells often Mesothelium is a single layer of cells that spread through lymph or blood. Lymph is a clear makes lubricating fluid and lines most organs fluid that gives cells water and food. It also has white inside the body. blood cells that fight germs. Lymph nodes are groups of disease-fighting cells that filter lymph and remove Connective tissue supports the mesothelium the germs. Lymph travels throughout the body in and supplies it with blood. Connective tissue vessels like blood does. As shown in Figure 2, attaches the pleura to other body parts. lymph vessels and nodes are found everywhere in the body. There is space between the visceral and parietal pleura called the pleural cavity. It is filled with a small Malignant pleural mesothelioma is the medical name amount of pleural fluid made by the mesothelium. for cancer that starts in the mesothelium of the lungs. Pleural fluid acts as a lubricant. It helps the two It is also simply called mesothelioma. It isn’t lung pleural layers slide against each other during cancer.
Load more

Recommended publications
  • Mediastinoscopic Esophagectomy with Lymph Node Dissection Using a Bilateral Transcervical and Transhiatal Pneumomediastinal Approach
    Tokairin et al. Mini-invasive Surg 2020;4:32 Mini-invasive Surgery DOI: 10.20517/2574-1225.2020.23 Technical Note Open Access Mediastinoscopic esophagectomy with lymph node dissection using a bilateral transcervical and transhiatal pneumomediastinal approach Yutaka Tokairin1,2, Yasuaki Nakajima2, Kenro Kawad2, Akihiro Hoshin2, Takuya Okada2, Toshihiro Matsui2, Kazuya Yamaguchi2, Kagami Nagai2, Yusuke Kinugasa2 1Department of Surgery, Toshima Hospital Tokyo Metropolitan Health and Hospitals Corporation, Tokyo 173-0015, Japan. 2Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8510, Japan. Correspondence to: Dr. Yutaka Tokairin, Department of Surgery, Toshima Hospital Tokyo Metropolitan Health and Hospitals Corporation, 33-1 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan. E-mail: [email protected] How to cite this article: Tokairin Y, Nakajima Y, Kawad K, Hoshin A, Okada T, Matsui T, Yamaguchi K, Nagai K, Kinugasa Y. Mediastinoscopic esophagectomy with lymph node dissection using a bilateral transcervical and transhiatal pneumomediastinal approach. Mini-invasive Surg 2020;4:32. http://dx.doi.org/10.20517/2574-1225.2020.23 Received: 17 Feb 2020 First Decision: 17 Mar 2020 Revised: 24 Mar 2020 Accepted: 1 Apr 2020 Published: 16 May 2020 Science Editor: Itasu Ninomiya Copy Editor: Jing-Wen Zhang Production Editor: Tian Zhang Abstract We developed a method for mediastinoscopic esophagectomy via a bilateral transcervical and transhiatal approach under pneumomediastinum as a less-invasive radical operation. The right recurrent nerve is first identified using an open approach, and the right cervical paraesophageal lymph nodes and part of the right recurrent nerve lymph nodes are dissected, after which pneumomediastinum is initiated.
    [Show full text]
  • NCCN Guidelines for Patients: Non-Small Cell Lung Cancer
    NCCN.org/patients/surveyPlease complete our online survey at NCCN Guidelines for Patients® Version 1.2016 Lung Cancer NON–SMALL CELL LUNG CANCER Presented with support from: Available online at NCCN.org/patients Ü NCCN Guidelines for Patients® Version 1.2016 Lung Cancer NON-SMALL CELL LUNG CANCER Learning that you have cancer can be overwhelming. The goal of this book is to help you get the best cancer treatment. It explains which cancer tests and treatments are recommended by experts of non-small cell lung cancer. The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 27 of the world’s leading cancer centers. Experts from NCCN have written treatment guidelines for doctors who treat lung cancer. These treatment guidelines suggest what the best practice is for cancer care. The information in this patient book is based on the guidelines written for doctors. This book focuses on the treatment of non-small cell lung cancer. Key points of the book are summarized in the related NCCN Quick Guide™. NCCN also offers patient resources on lung cancer screening as well as other cancer types. Visit NCCN.org/patients for the full library of patient books, summaries, and other patient and caregiver resources. ® NCCN Guidelines for Patients i Lung Cancer – Non-Small Cell, Version 1.2016 Endorsers and sponsors Endorsed and sponsored in part by LUNG CANCER ALLIANCE LUNG CANCER RESEARCH COUNCIL Lung Cancer Alliance is proud to collaborate with National Comprehensive As an organization that seeks to increase public awareness and Cancer Network to sponsor and endorse these NCCN Guidelines for understanding about lung cancer and support programs for screening and Patients®: Non–Small Cell Lung Cancer.
    [Show full text]
  • Alternative – Universal Extended Video Mediastinoscopy with Distending, Narrow Blades Extended Video Mediastinoscopy with Distending, Tapered Blade System
    THOR 19 2.0 11/2020-E Alternative – Universal Extended video mediastinoscopy with distending, narrow blades Extended video mediastinoscopy with distending, tapered blade system By creating visibility and space, video mediastinoscopy allows the precise display and dissection of mediastinal structures and is therefore valuable for lymph node staging. Mediastinal staging as well as extended or complex endoscopic interventions, including video-assisted mediastinoscopic lymphadenectomy (VAMLA), can be performed with the aid of a distending video mediastinoscope system. KARL STORZ offers an atraumatic, easy-to-use, compact blade system with a holding arm device and an integrated irrigation and suction channel for this purpose. Two adjustment wheels in the handle allow distal distension of the blades and height adjustment in parallel. Combined with a matching HOPKINS® wide angle telescope, this autoclavable blade system provides the operating surgeon with an optimal overview of the working area. In conjunction with a holding arm with KSLOCK, bimanual work is also possible. The corresponding DCI® camera head IMAGE1 S™ D1 is operated via the modular KARL STORZ IMAGE1 S™ camera platform. Consequently, the system is likely to experience a renaissance in the coming years. We also offer instruments and other accessories that are compatible with the system. © KARL STORZ 96082019 THOR 19 2.0 11/2020 EW-E 2 Components of the KARL STORZ video mediastinoscopy system for extended mediastinoscopy Monitor 27" FULL HD Monitor TM220 Camera System IMAGE1 S CONNECT®
    [Show full text]
  • Mediastinoscopy: a Clinical Evaluation of 400 Consecutive Cases
    Thorax: first published as 10.1136/thx.24.5.585 on 1 September 1969. Downloaded from Thorax (1969), 24, 585. Mediastinoscopy: A clinical evaluation of 400 consecutive cases C. L. SARIN1 AND H. C. NOHL-OSER From the Thoracic Surgical Unit, Harefield Hospital, Harefield, Middlesex Mediastinoscopy was carried out in 400 cases, including 296 of bronchogenic carcinoma. At the time of presentation the new growth had already spread to involve the mediastinal lymph nodes in slightly more than 50% of these. The incidence of involvement was 76% in oat-cell and 35% in squamous-cell carcinoma. Non-resectability at thoracotomy was encountered in seven out of 120 patients. We advocate this procedure in every case of bronchogenic carcinoma which is considered operable on other counts. In patients in whom the mediastinal lymph nodes are invaded by growth we prefer radical radiotherapy to surgery, as the long-term survival of the two methods is comparable. This procedure may be the only source of positive histological proof of diagnosis, not only in carcinoma but in other types of intrathoracic disease. We believe that this procedure reduces the number of unnecessary exploratory thoracotomies. Carlens (1959) introduced diagnostic exploration sible. Biopsy in such cases can be obtained from tissues inside the thoracic inlet. in the of the superior mediastinum. The space explored just Bleeding, copyright. is part of the superior mediastinum which is presence of incipient or developed superior vena caval of the obstruction, or dense fibrosis of the pre-tracheal situated around tihe intrathoracic part fascia, can make the procedure difficult or impossible.
    [Show full text]
  • Cervical Mediastinal L SUSAN ALEXANDER L for STAGING of LUNG CANCER
    Cervical Mediastinal l SUSAN ALEXANDER l FOR STAGING OF LUNG CANCER ervical mediastinal exp- bronchogenic lung cancer by sam- loration (CME), or pling selected lymph nodes in and mediastinoscopy, is a around the trachea, its major surgical procedure to bifurcation and the great vessels. C explore and sample Lymph nodes are removed and lymph nodes in the space between sent to pathology for tissue diag- the lungs, (the mediastinum), nosis to determine the histology when diagnostic imaging studies of the tumor. CME is performed (X-ray, CT scan, etc) suggest a primarily to stage lung cancer growth in the lungs or mediasti- and determine the extent of the nal region. The most common pur- disease and establish treatment pose of the CME is to diagnose options. DECEMBER 2002 The Surgical Technologist 9 224 DECEMBER 2002 CATEGORY 1 If cancer exists in the lymph nodes, the cell type nodes that are not accessible through CME. In (histology) identifies the type of cancer and one series of 100 patients with tumors in this extent of the lymph nodes involved. If tumor area, 22 were found to be inoperable despite hav­ involvement in the mediastinal area is demon­ ing a negative mediastinoscopy.5 Left anterior strated in the pathology review of the speci- mediastinotomy through the second intercostal men(s) (lymph nodes), the patient may be space is the preferred method to assess the oper­ spared an unnecessary thoracotomy; however, ability of these patients, as suggested by Pearson this means that the tumor is inoperable.5 and coworkers.5 Less than 50% of patients undergoing cura­ History tive resection for bronchogenic carcinoma sur­ CME was originally described by Harken and vive five years.
    [Show full text]
  • Experience with Video Mediastinoscopy at a Tertiary Cancer Center
    Oncology and Radiotherapy © 1 (50) 2020: 001-005 • RESEARCH ARTICLE From radiological assumption to pathological conviction: experience with video mediastinoscopy at a tertiary cancer center Nizamudheen MP, Abhay K Kattepur, Satheesan B Department of Surgical Oncology, Malabar Cancer Centre, Thalassery, Kerala, India Purpose: To describe the role of mediastinoscopy in the setting of mediastinaladenopathy secondary to pulmonary and non-pulmonary cancers. INTRODUCTION Methods: Retrospective analysis of patients undergoing video mediastinoscopy SUMMARY from November 2016 to December 2018 at tertiary cancer center for Cervical mediastinoscopy is a time tested tool for the mediastinaladenopathy from lung cancer and non-pulmonary cancers with invasive staging of mediastinal nodes. Standard cervical mediastinal nodes. mediastinoscopy helpsin approaching lymph node stations viz. Results: Twelve patients were included out of which 11 patients underwent right upper paratracheal (station 2R), right lower paratracheal diagnostic mediastinoscopy. The median age was 58 years. Seven patients had lung cancer. The mean number of nodes sampled was 10.5 (range: (4R), left upper paratracheal (2L), right lower paratracheal 2-28 nodes). Five patients had mediastinaladenopathy from non-pulmonary (4L) and sub-carinal (7). Hilar nodes (station 10) can also cancer like endometrial, oropharyngeal and Hodgkin’s lymphoma. Recurrent laryngeal nerve palsy was noted in one patient. be accessed byexperienced surgeons, although it can be Conclusion: Mediastinoscopy serves as a valuable asset for staging of lung technically challenging. Overall, this procedure is accurate and cancer and in the assessment of suspicious nodes in the setting of non- carries minimal morbidity [1]. The role of mediastinoscopy pulmonary cancers. However, training and expertise is in the need of the hour to prevent redundancy of this valuable procedure.
    [Show full text]
  • 3D Printed Model of the Mediastinum for Cardiothoracic Surgery Resident Education Natalie S
    3D printed model of the mediastinum for cardiothoracic surgery resident education Natalie S. Lui MD1, Winston Trope1, H. Henry Guo MD PhD2, Kyle Gifford2, Prasha Bhandari MPH1, Jalen Benson1, Douglas Z. Liou MD1, Leah M. Backhus MD MPH1, Mark F. Berry MD1, Joseph B. Shrager MD1 Divisions of 1Thoracic Surgery and 2Radiology, Stanford University School of Medicine, Stanford, CA Purpose Results Conclusion Mediastinoscopy remains the gold standard for mediastinal lymph node There were 51 resident self assessments and 65 attending assessments completed over A novel, 3D printed model of the mediastinum was an staging, but residents are performing fewer of them with the development of two years. (Residents and attendings could complete more than one assessment). effective tool for teaching cardiothoracic surgery endobronchial ultrasound. We hypothesized that a three-dimensional (3D) General surgery, integrated cardiac residents, and traditional thoracic and cardiac track residents the anatomy and techniques for printed model of the mediastinum would be an effective tool for teaching fellows were included. mediastinoscopy, as measured by resident self assessment and attending assessment. 3D printing is a residents the anatomy and techniques for mediastinoscopy. Residents taught with the 3D model (n=22) were more likely to respond “well” or “very promising technology with many potential applications Methods well” for three of the four self assessment questions. Attendings were more likely to in cardiothoracic surgery resident education. Computed tomography images were segmented using Materialise Mimics respond “very well” to two of the assessment questions. (Figure 4) (Materialise, Leuven, Belgium), and a color model of the mediastinum was Figure 4. Resident self assessments (A) and attending assessments (B) comparing 3D printed using a Stratasys J735 (Stratasys, Eden Prairie, MN).
    [Show full text]
  • Patient Education Handbook As Soon As I Was Diagnosed with Lung Cancer
    NAVIGATING LUNG CANCER NAVIGATING LIFE DOESN’T COME WITH INSTRUCTIONS, BUT LIVING WITH LUNG CANCER NOW HAS THIS SURVIVOR’S GUIDEBOOK. NAVIGATING INSIDE YOU WILL GET THE MOST UP-TO-DATE NAVIGATION TOOLS ON: • THE DIAGNOSIS PROCESS • LIVING WITH LUNG CANCER • LUNG CANCER STAGING • FINANCING YOUR CARE LUNG CANCER • TREATMENT OPTIONS • HOPE FOR SURVIVING LUNG CANCER • CLINICAL TRIALS • AND MORE In my house we call it “the lung bible.” It has been an invaluable resource 360º OF HOPE for me, my family and (sadly) a newly diagnosed friend. FIFTH EDITION – FALL 2020 —Diane Broderick I love this handbook! It has great information that I have shared with my family and friends. I often pick it up and re-read. Each time I learn something new, or it triggers something that I need to talk to my doctor(s) about. —Kimberly Buchmeier 360º OF HOPE When my husband was first diagnosed with stage IV Adenocarcinoma we were paralyzed with fear and found ourselves starved for good information about the fight we were beginning. The University of Colorado/ Anchutz hospital advised us to contact the foundation and we were sent this wonderful handbook that answered all of our questions and enabled us to feel knowledgeable when choosing an oncologist and when facing surgery and treatments. It is an invaluable resource to us. —Peter & Donna Blum This is the most comprehensive manual I’ve ever seen written...focused for the lung cancer patient. BONNIE —Roy S. Herbst, MD, PhD BONNIE J. ADDARIO Ensign Professor of Medicine (Oncology), Professor of Pharmacology, Chief of Medical Oncology, Associate Director for Translational Research, Director—Thoracic Oncology SURVIVOR Research Program, Yale Comprehensive Cancer Center, Yale School of Medicine J.
    [Show full text]
  • Experience with Mediastinoscopy
    Thorax: first published as 10.1136/thx.27.4.463 on 1 July 1972. Downloaded from Thorax (1972), 27, 463. Experience with mediastinoscopy T. L. OTTO, J. ZASLONKA and M. LUKIA?4SKI Institute of Tuberculosis and Chest Diseases, Warsaw, Second Surgical Department, Medical Academy. Lodi, and Department of Thoracic Surgery, Institute of Postgraduate Studies, Zakopane, Poland Six hundred and eighty diagnostic mediastinoscopies are presented. Of these, 552 were classical, 114 anterior mediastinal, 12 posterior mediastinal, and 2 from below the sternum. In addition, 20 therapeutic mediastinoscopies were performed for the insertion of a pacemaker electrode or evacuation of a mediastinal cyst. Of 125 mediastinoscopies performed on patients with an initial diagnosis of sarcoidosis, in most the diagnosis was confirmed, the rate of false negative results being 2-4%. Extremely encouraging were the results in patients with an initial diagnosis of Hodgkin's disease. Out of 60 patients, a different diagnosis was established in 30 and further follow-up proved this to be correct. In mediastinal tumours the results were discouraging, the rate of false results being as high as 43%. Four hundred and ten patients were mediastinoscoped for lung cancer. In 52, mediastino- scopy was the first successful biopsy. Metastases to lymph nodes were found in 139 (33-9%). The percentage of exploratory thoracotomies following the introduction of mediastinoscopy fell from 22% to 14%. Mediastinoscopy was also used to investigate the spread of oesophageal cancer and enabled us to exclude patients who were obviously inoperable. Mediastinal and pulmonary diseases involving the phagus and to take biopsies of mediastinal tumours. http://thorax.bmj.com/ lymphatic system often present considerable diag- Carlens himself tried to introduce mediastinoscopy nostic difficulties.
    [Show full text]
  • Anesthesia for Patients with Mediastinal Masses
    14 Anesthesia for Patients with Mediastinal Masses Chih Min Ku Introduction .................................................................................................................. 201 Anatomy and Pathology ............................................................................................... 202 Clinical Presentation .................................................................................................... 202 Preoperative Evaluation ............................................................................................... 203 Surgical Approaches .................................................................................................... 203 Preoperative Treatment ................................................................................................ 203 Anesthetic Management ............................................................................................... 203 Complications and Risk Factors .................................................................................. 205 Anesthesia for Mediastinoscopy .................................................................................. 205 Summary ...................................................................................................................... 206 Clinical Case Discussion .............................................................................................. 207 Key Points • A careful anesthetic plan that is not irreversible is likely to result in a good outcome. • Patients with anterior mediastinal
    [Show full text]
  • Mediastinoscopy
    cancer.org | 1.800.227.2345 Mediastinoscopy What is mediastinoscopy? Mediastinoscopy is a procedure a doctor uses to look inside the mediastinum – the area behind the breastbone and between the lungs. This is done with a mediastinoscope, a thin, flexible tube with a light, small video camera and cutting tool on the end. The tube is put through a small cut made just above the breastbone and slowly moved into the mediastinum. Why do you need to have mediastinoscopy? Because the lymph nodes or the area between your lungs looks suspicious Mediastinoscopy is often done to remove or biopsy lymph nodes in the area between the lungs to check for cancer or to stage lung cancer1. It can also be used in people with thymoma2 (tumor of the thymus gland), esophagus cancer3, or lymphoma4 for the same reasons. What’s it like to have a mediastinoscopy? This is what typically happens before, during, and after a mediastinoscopy. But your experience might be a little different, depending on things like why you’re having the test, where you’re having the test done, and your overall health. Be sure to talk to your health care provider before having this test so you understand what to expect and ask questions if you’re not sure about something. Before the test Be sure your health care provider knows about any medicines you are taking, including 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 vitamins, herbs, and supplements, as well as if you have allergies to any medicines. You might be asked to stop taking blood-thinning medicines (including aspirin) for several days before the test.
    [Show full text]
  • Surgical Instruments Catalog German Engineering
    surgical insTrumenTs caTalog German Engineering. American Design. World-Class Quality. Teleflex, KMedic and Pilling are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. Teleflex is a global provider of medical products designed to enable healthcare providers to protect against infections and improve patient and provider safety. The company specializes in products and services for vascular access, respiratory, general and regional anesthesia, cardiac care, urology and surgery. Teleflex also provides specialty products for device manufacturers. © 2013 Teleflex Incorporated. All rights reserved. 2013-2241 Teleflex PO Box 12600 Research Triangle Park, NC 27709 Toll Free: 866.246.6990 Phone: +1.919.544.8000 Teleflex.com GENERAL INFORMATION Bougies/Dilators . 465 Tracheostomy Tubes . 469 Ear Instruments . 493 Nasal Instruments . 503 Mouth and Throat Instruments . 521 Scope and Light Carriers Identification Index . 534 CARDIAC, VASCULAR AND THORACIC INSTRUMENTS Overview . 542 CVT Forceps and Clamps . 544 Bulldog® and Micro Vessel Clamps . 560 Pilling® Vascular Clamps . 573 Vascular Clamps . 575 Aortic Vascular Clamps . 628 Scissors . 656 CVT Needle Holders . 674 Titanium Instruments: Forceps and Clamps . 686 Titanium Instruments: Scissors . 704 Titanium Instruments: Needle Holders . 707 Rib Instruments . 714 CVT Retractors . 720 Valve Instruments . 751 Aortic Punches . 762 Heparin Cannulae . 764 Suction Tubes . 765 Vascular Dilators . 768 Valvulotomes . 772 Mediastinoscopy . 774 Video-Assisted Thoracoscopy . 780 Miscellaneous CVT . 793 Specialty Sets . 798 ORTHOPEDIC INSTRUMENTS Overview . 804 KMedic® Wire And Pin Implants . 806 Kirschner Wires, Steinmann Pin, Vickers K-Wire Dispensers . 809 Vickers Easidriver . 812 KMedic® Gratloch™ Wire Bender . 814 Wire Twisters And Wire/Pin/Rod Cutters . 816 KMedic® Corwin Wire Twister . 819 KMedic® P .I . Wire Twister And Tightener .
    [Show full text]